{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:07:17Z","timestamp":1790770037491,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Servier through a research grant to the EU-ADR Alliance","award":["."],"award-info":[{"award-number":["."]}]},{"name":"National Institute for Health Research Clinician Scientist award","award":["CS-2013-13-012"],"award-info":[{"award-number":["CS-2013-13-012"]}]},{"name":"NIHR Biomedical Research Centre, Oxford.","award":["."],"award-info":[{"award-number":["."]}]},{"name":"Erasmus Medical centre","award":["."],"award-info":[{"award-number":["."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00198-020-05580-0","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T11:02:56Z","timestamp":1596625376000},"page":"2425-2438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comparative cardiovascular safety of strontium ranelate and bisphosphonates: a multi-database study in 5 EU countries by the EU-ADR Alliance"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4192-7908","authenticated-orcid":false,"given":"M.S.","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Berencsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Marinier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Deltour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Perez-Guthann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rijnbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Van der Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sturkenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Prieto-Alhambra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,5]]},"reference":[{"key":"5580_CR1","unstructured":"European Medicines Agency (2013) PSUR assessment report. EMA\/PRAC\/136656\/2013. Strontium ranelate"},{"key":"5580_CR2","unstructured":"European Medicines Agency (2013) Recommendation to restrict the use of Protelos \/ Osseor (strontium ranelate)"},{"key":"5580_CR3","unstructured":"European Medicines Agency (2014) Protelos\/Osseor to remain available but with further restrictions"},{"key":"5580_CR4","unstructured":"European Medicines Agency (2014) Protelos and Osseor. CHMP scientific conclusions and PRAC Assessment report of the Review under Article 20 of Regulation (EC) No 726\/2004"},{"issue":"2","key":"5580_CR5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00198-013-2469-4","volume":"25","author":"B Abrahamsen","year":"2014","unstructured":"Abrahamsen B, Grove E, Vestergaard P (2014) Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporos Int 25(2):757\u2013762","journal-title":"Osteoporos Int"},{"issue":"6","key":"5580_CR6","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1136\/annrheumdis-2014-205283","volume":"73","author":"H Svanstr\u00f6m","year":"2014","unstructured":"Svanstr\u00f6m H, Pasternak B, Hviid A (2014) Use of strontium ranelate and risk of acute coronary syndrome: cohort study. Ann Rheum Dis 73(6):1037\u20131043","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5580_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00198-013-2582-4","volume":"25","author":"C Cooper","year":"2014","unstructured":"Cooper C, Fox K, Borer J (2014) Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case\u2013control study in the CPRD. Osteoporos Int 25(2):737\u2013745","journal-title":"Osteoporos Int"},{"issue":"6","key":"5580_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-002862","volume":"3","author":"PM Coloma","year":"2013","unstructured":"Coloma PM, Valkhoff VE, Mazzaglia G, Nielsson MS, Pedersen L, Molokhia M, Mosseveld M, Morabito P, Schuemie MJ, van der Lei J, Sturkenboom M, Trifir\u00f2 G, on behalf of the EU-ADR Consortium (2013) Identification of acute myocardial infarction from electronic healthcare records using different disease coding systems: a validation study in three European countries. BMJ Open 3(6):e002862","journal-title":"BMJ Open"},{"issue":"1","key":"5580_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.recesp.2011.07.017","volume":"65","author":"R Ramos","year":"2012","unstructured":"Ramos R, Ball\u00f3 E, Marrugat J, Elosua R, Sala J, Grau M, Vila J, Bol\u00edbar B, Garc\u00eda-Gil M, Mart\u00ed R, Fina F, Hermosilla E, Rosell M, Mu\u00f1oz MA, Prieto-Alhambra D, Quesada M (2012) Validity for use in research on vascular diseases of the SIDIAP (information system for the development of research in primary care): the EMMA study. Rev Esp Cardiol (English Edition) 65(1):29\u201337","journal-title":"Rev Esp Cardiol (English Edition)"},{"issue":"6","key":"5580_CR10","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1046\/j.1365-2125.2000.00199.x","volume":"49","author":"R Lawrenson","year":"2000","unstructured":"Lawrenson R, Todd JC, Leydon G, Williams T, Farmer R (2000) Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 49(6):591\u2013596","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"5580_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jclinepi.2009.03.018","volume":"63","author":"MT Severinsen","year":"2010","unstructured":"Severinsen MT, Kristensen SR, Overvad K, Dethlefsen C, Tj\u00f8nneland A, Johnsen SP (2010) Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution. J Clin Epidemiol 63(2):223\u2013228","journal-title":"J Clin Epidemiol"},{"key":"5580_CR12","doi-asserted-by":"publisher","first-page":"S368","DOI":"10.1016\/j.jval.2018.09.2198","volume":"21","author":"C Reyes","year":"2018","unstructured":"Reyes C, Aragon M, Rijnbeek P, van der Lei J, Verhamme K, Prieto-Alhambra D (2018) Validation of COPD ICD10 diagnostic codes in the SIDIAP primary health care research database using a combination of spirometry measures, symptoms, drug use, and free text review. Value Health 21:S368","journal-title":"Value Health"},{"key":"5580_CR13","unstructured":"R Core Team (2013) R: A language and environment for statistical computing"},{"issue":"4","key":"5580_CR14","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00198-019-05181-6","volume":"31","author":"K Berencsi","year":"2020","unstructured":"Berencsi K, Sami A, Ali MS, Marinier K, Deltour N, Perez-Gutthann S, Pedersen L, Rijnbeek P, van der Lei J, Lapi F, Simonetti M, Reyes C, Sturkenboom MCJM, Prieto-Alhambra D (2020) Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance. Osteoporos Int 31(4):721\u2013755","journal-title":"Osteoporos Int"},{"key":"5580_CR15","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Merino E, Petersen I, Hawley S et al (2018) Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK. Osteoporos Int 29(2):467\u2013478","DOI":"10.1007\/s00198-017-4308-5"},{"issue":"8","key":"5580_CR16","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1002\/jbmr.3448","volume":"33","author":"C-W Sing","year":"2018","unstructured":"Sing C-W, Wong AYS, Kiel DP et al (2018) Association of alendronate and risk of cardiovascular events in patients with hip fracture. J Bone Miner Res 33(8):1422\u20131434","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05580-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-020-05580-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05580-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T23:14:42Z","timestamp":1628118882000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-020-05580-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,5]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5580"],"URL":"https:\/\/doi.org\/10.1007\/s00198-020-05580-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,5]]},"assertion":[{"value":"12 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The manuscript is accompanied by completed \u2018Authorship & Disclosure Form\u2019.All authors have completed the ICMJE uniform disclosure form at  and declare SPG as employee of RTI Health Solutions receives grants and consultation from pharmaceutical companies including Servier for other regulatory safety studies and for supporting the role in the scientific advisory board for this study; DPA\u2019s department has received fees for speaker services and advisory board membership from Amgen, consultancy fees from UCB Biopharma, and research grants from UCB Biopharma and Amgen; KM and ND are employees of Servier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and\/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}